European OTC Results Round-Up: Alliance Pharma, Boiron and Ipsen
UK-based Alliance Pharma reported a good year for its OTC business in 2018, while French players Boiron and Ipsen endured a more difficult 12 months.
You may also be interested in...
Boiron Balks As France Looks To De-Reimburse Homeopathic Medicines
The French health watchdog Haute Autorité de Santé's recommendation to de-reimburse homeopathic medicines ignores their health benefits and popularity among French consumers, insists Laboratoires Boiron.
J&J Divests OTC Anti-Dandruff Product To Separate Buyers Across 3 Regions
J&J agrees to sell marketing rights to its OTC 1% ketoconazole dandruff treatment product to Kramer Labs in the US and Latin America, to German firm Stada in the EMEA and to UK firm Alliance Pharma for the Asia-Pacific market as it continues to spin off non-core brands and focus on its core $1bn brands.
People On The Move: Appointments At AESGP, Alliance Pharma, FSE, Venture Life
A round-up of the latest appointments in Europe's consumer health industry: AESGP names Haleon's Workman as president; Alliance Pharma shareholders re-elect board; Food Supplements Europe re-elects Stada's Šímová as chair; and Venture Life announces departure of co-Founder and CCO Daly.